NCT03093922

A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer

Atezolizumab in Combination With Gemcitabine and Cisplatin As First-Line Treatment in Metastatic Urothelial Cancer: A Multicenter Randomized Phase II Study of Two Alternative Dosing Schedules

• Status: Active Not Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 32 (actual)
• Sponsor: Memorial Sloan Kettering Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to compare any good and bad effects the study drug atezolizumab has on the cancer when combined with the standard chemotherapy drugs gemcitabine and cisplatin (or GC) in two different dosing schedules: chemotherapy (GC) before atezolizumab vs. GC after atezolizumab.

Conditions

• Urothelial Carcinoma
• Locally Advanced
• Unresectable

Interventions

Type	Name	Description
DRUG	Atezolizumab	1200 mg/m\^2
DRUG	Gemcitabine	1000 mg/m\^2
DRUG	Cisplatin	70 mg/m\^2

Timeline

• Start date: 2017-03-22
• Primary completion: 2027-03-01
• Completion: 2027-03-01
• First posted: 2017-03-28
• Last updated: 2026-04-07

Locations

9 sites across 1 country: United States

Regulatory

• FDA-regulated drug study